Literature DB >> 15378077

Concepts of human leukemic development.

Jennifer K Warner1, Jean C Y Wang, Kristin J Hope, Liqing Jin, John E Dick.   

Abstract

Two fundamental problems in cancer research are identification of the normal cell within which cancer initiates and identification of the cell type capable of sustaining the growth of the neoplastic clone. There is overwhelming evidence that virtually all cancers are clonal and represent the progeny of a single cell. What is less clear for most cancers is which cells within the tumor clone possess tumorigenic or 'cancer stem cell' (CSC) properties and are capable of maintaining tumor growth. The concept that only a subpopulation of rare CSC is responsible for maintenance of the neoplasm emerged nearly 50 years ago. Testing of this hypothesis is most advanced for the hematopoietic system due to the establishment of functional in vitro and in vivo assays for stem and progenitor cells at all stages of development. This body of work led to conclusive proof for CSC with the identification and purification of leukemic stem cells capable of repopulating NOD/SCID mice. This review will focus on the historical development of the CSC hypothesis, the mechanisms necessary to subvert normal developmental programs, and the identification of the cell in which these leukemogenic events first occur.

Entities:  

Mesh:

Year:  2004        PMID: 15378077     DOI: 10.1038/sj.onc.1207933

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  53 in total

1.  [Risk-adapted therapy in acute myeloid leukemia].

Authors:  M Fiegl; W Hiddemann
Journal:  Internist (Berl)       Date:  2012-04       Impact factor: 0.743

2.  Cell intrinsic alterations underlie hematopoietic stem cell aging.

Authors:  Derrick J Rossi; David Bryder; Jacob M Zahn; Henrik Ahlenius; Rebecca Sonu; Amy J Wagers; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-20       Impact factor: 11.205

3.  Memory T and memory B cells share a transcriptional program of self-renewal with long-term hematopoietic stem cells.

Authors:  Chance John Luckey; Deepta Bhattacharya; Ananda W Goldrath; Irving L Weissman; Christophe Benoist; Diane Mathis
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-21       Impact factor: 11.205

4.  Meeting report: Seventh International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia, Annapolis, MD, May 13-16, 2007.

Authors:  Linda Wolff; Steven J Ackerman; Giuseppina Nucifora
Journal:  Exp Hematol       Date:  2008-03-04       Impact factor: 3.084

Review 5.  Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches.

Authors:  Marina Konopleva; Yoko Tabe; Zhihong Zeng; Michael Andreeff
Journal:  Drug Resist Updat       Date:  2009-07-25       Impact factor: 18.500

6.  A mathematical model of subpopulation kinetics for the deconvolution of leukaemia heterogeneity.

Authors:  María Fuentes-Garí; Ruth Misener; David García-Munzer; Eirini Velliou; Michael C Georgiadis; Margaritis Kostoglou; Efstratios N Pistikopoulos; Nicki Panoskaltsis; Athanasios Mantalaris
Journal:  J R Soc Interface       Date:  2015-07-06       Impact factor: 4.118

7.  CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemia.

Authors:  Naoki Hosen; Christopher Y Park; Naoya Tatsumi; Yusuke Oji; Haruo Sugiyama; Martin Gramatzki; Alan M Krensky; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-06-18       Impact factor: 11.205

Review 8.  Molecular pathogenesis of MLL-associated leukemias.

Authors:  Mariko Eguchi; Minenori Eguchi-Ishimae; Mel Greaves
Journal:  Int J Hematol       Date:  2005-07       Impact factor: 2.490

9.  Mathematical modeling of therapeutic strategies for myeloid malignancies.

Authors:  Dan Wu; Huiyu Li; Wen Du; Xiaoxia Ji; Wei Liu; Shiang Huang; Yi Xiao
Journal:  Pathol Oncol Res       Date:  2012-10       Impact factor: 3.201

Review 10.  Biology of normal and acute myeloid leukemia stem cells.

Authors:  John E Dick; Tsvee Lapidot
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.